Pasar al contenido principal

ANALISIS FUNCIONAL DE LA INACTIVACION DE COMPLEJOS INVOLUCRADOS EN LA REPRESION TRANSCRIPCIONAL EN EL DESARROLLO DEL CANCER DE PULMON.

PID2020-114541RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

  • Alburquerque-Bejar, Juan J.
  • Navajas-Chocarro, Pablo
  • Saigi, Maria
  • Ferrero-Andrés, Ana
  • Morillas, Juan M.
  • Vilarrubi, Andrea
  • Gómez, Antonio
  • Mate, José Luís
  • Muñoz-Mármol, Ana María
  • Romero, Octavio A.
  • Blecua, Pedro
  • Davalos, Veronica
  • Esteller, Manel
  • Pros, Eva
  • Llabata, Paula
  • Torres-Diz, Manuel
  • Esteve-Codina, Anna
  • Sánchez Céspedes, Montse
Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study the cell-intrinsic response of lung cancer (LC) to interferon-γ (IFNγ), a cytokine that promotes immunoresponse and modulates programmed death-ligand 1 (PD-L1) levels. We report complete refractoriness to IFNγ in a subset of LCs as a result of JAK2 or IFNGR1 inactivation. A submaximal response affects another subset that shows constitutive low levels of IFNγ-stimulated genes (IγSGs) coupled with decreased H3K27ac (histone 3 acetylation at lysine 27) deposition and promoter hypermethylation and reduced IFN regulatory factor 1 (IRF1) recruitment to the DNA on IFNγ stimulation. Most of these are neuroendocrine small cell LCs (SCLCs) with oncogenic MYC/MYCL1/MYCN. The oncogenic activation of MYC in SCLC cells downregulates JAK2 and impairs IγSGs stimulation by IFNγ. MYC amplification tends to associate with a worse response to anti-PD1/L1 therapies. Hence alterations affecting the JAK/STAT pathway and MYC activation prevent stimulation by IFNγ and may predict anti-PD1/L1 efficacy in LC., The authors thank Isabel Bartolessis (Cancer Genetics Group) and Eva Mussolen (Cancer Epigenetics Group) at IJC for technical assistance. This work was supported by Spanish grants from the MINECO (PID2020-114541RB-I00 to M.S.-C.) and from the Fundación Científica Asociación Española Contra el Cáncer (GCB14142170MONT to M.S.-C.). P.L. was supported by a fellowship from the Formación de Personal Investigador program (BES-2015-072204) and J.M.M. from the FI program AGAUR (2022 FI_B1 00085M). M.S. was supported by a Juan Rodes contract from the Instituto de Salud Carlos III (JR20/00015). O.A.R. was supported by an AECC contract (INVES19045ROME). We thank the CERCA Program/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

  • Alburquerque-Bejar, Juan J.
  • Navajas-Chocarro, Pablo
  • Saigi, Maria
  • Ferrero-Andrés, Ana
  • Morillas, Juan M.
  • Vilarrubi, Andrea
  • Gómez, Antonio
  • Mate, José Luís
  • Muñoz-Mármol, Ana María
  • Romero, Octavio A.
  • Blecua, Pedro
  • Davalos, Veronica
  • Esteller, Manel
  • Pros, Eva
  • Llabata, Paula
  • Torres-Diz, Manuel
  • Esteve-Codina, Anna
  • Sánchez Céspedes, Montse
Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study the cell-intrinsic response of lung cancer (LC) to interferon-γ (IFNγ), a cytokine that promotes immunoresponse and modulates programmed death-ligand 1 (PD-L1) levels. We report complete refractoriness to IFNγ in a subset of LCs as a result of JAK2 or IFNGR1 inactivation. A submaximal response affects another subset that shows constitutive low levels of IFNγ-stimulated genes (IγSGs) coupled with decreased H3K27ac (histone 3 acetylation at lysine 27) deposition and promoter hypermethylation and reduced IFN regulatory factor 1 (IRF1) recruitment to the DNA on IFNγ stimulation. Most of these are neuroendocrine small cell LCs (SCLCs) with oncogenic MYC/MYCL1/MYCN. The oncogenic activation of MYC in SCLC cells downregulates JAK2 and impairs IγSGs stimulation by IFNγ. MYC amplification tends to associate with a worse response to anti-PD1/L1 therapies. Hence alterations affecting the JAK/STAT pathway and MYC activation prevent stimulation by IFNγ and may predict anti-PD1/L1 efficacy in LC., The authors thank Isabel Bartolessis (Cancer Genetics Group) and Eva Mussolen (Cancer Epigenetics Group) at IJC for technical assistance. This work was supported by Spanish grants from the MINECO (PID2020-114541RB-I00 to M.S.-C.) and from the Fundación Científica Asociación Española Contra el Cáncer (GCB14142170MONT to M.S.-C.). P.L. was supported by a fellowship from the Formación de Personal Investigador program (BES-2015-072204) and J.M.M. from the FI program AGAUR (2022 FI_B1 00085M). M.S. was supported by a Juan Rodes contract from the Instituto de Salud Carlos III (JR20/00015). O.A.R. was supported by an AECC contract (INVES19045ROME). We thank the CERCA Program/Generalitat de Catalunya for institutional support.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Navajas-Chocarro, Pablo
  • Saigí, Maria|||0000-0001-5815-5388
  • Ferrero-Andres, Ana
  • Morillas, Juan M.
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Mate, José L.
  • Munoz-Marmol, Ana M.
  • Romero, Octavio A.|||0000-0003-0229-6530
  • Blecua, Pedro|||0000-0002-1012-0300
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M.|||0000-0003-4490-6093
  • Pros, Eva|||0000-0002-2366-7866
  • Llabata, Paula|||0000-0001-7733-6475
  • Torres-Diz, Manuel
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study the cell-intrinsic response of lung cancer (LC) to interferon-γ (IFNγ), a cytokine that promotes immunoresponse and modulates programmed death-ligand 1 (PD-L1) levels. We report complete refractoriness to IFNγ in a subset of LCs as a result of JAK2 or IFNGR1 inactivation. A submaximal response affects another subset that shows constitutive low levels of IFNγ-stimulated genes (IγSGs) coupled with decreased H3K27ac (histone 3 acetylation at lysine 27) deposition and promoter hypermethylation and reduced IFN regulatory factor 1 (IRF1) recruitment to the DNA on IFNγ stimulation. Most of these are neuroendocrine small cell LCs (SCLCs) with oncogenic MYC/MYCL1/MYCN. The oncogenic activation of MYC in SCLC cells downregulates JAK2 and impairs IγSGs stimulation by IFNγ. MYC amplification tends to associate with a worse response to anti-PD1/L1 therapies. Hence alterations affecting the JAK/STAT pathway and MYC activation prevent stimulation by IFNγ and may predict anti-PD1/L1 efficacy in LC.